Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia

Park, Jong Seon; Kim, Young Jo; Choi, Ji Yong; Kim, Yoon Nyun; Hong, Teck Jong; Kim, Dong Soo; Kim, Ki Young; Jeong, Jin‐Ok; Chae, Jei Keon; Oh, Seok Kyu; Seong, In Whan

doi:10.3904/kjim.2010.25.1.27

Cited by 38 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Park et al, in the study with 351 Korean patients with metabolic syndrome and hypercholesterolemia found greater reduction in TC and LDL-C level by Rosuvastatin treatment as compared to Atorvastatin treatment which is similar with the result of my study. 22 A 48 week randomized, parallel group, open label study done in 106 patients with primary hypercholesterolemia by Mazza et al, showed that Rosuvastatin was associated with significantly greater reduction in LDL-C, TC, and TG compared to Atorvastatin which resembles with the result of my study. 23 A comparative study done by Otokozawa et al, also showed that maximum dose Rosuvastatin 40mg/day was significantly more effective than Atorvastatin 80mg/day in reducing LDL-C, TG and TC which supports the result of my study.…”

Section: Discussionsupporting

confidence: 76%

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Thapa¹,

Rai²,

Mahara³

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

INTRODUCTIONWorldwide, hypercholesterolemia cause about 56% of ischemic heart disease and 18% of strokes, resulting to 4.4 million deaths annually. Hyperlipidemia and the rates of hypercholesterolemia (total cholesterol ≥201.1mg/dl) increased from 18% to 31% in adults aged 35-59. 1 Studies have shown that the risk of ischemic heart disease in individuals with hypercholesterolemia is about thrice as great as in those with normal plasma cholesterol level indicating that reduction in plasma cholesterol does reduce the risk of myocardial infraction. 2There is increasing evidence that Hyperlipidemia is a major cause of atherosclerosis and atherosclerosisassociated conditions, such as coronary heart disease (CHD), ischemic cerebrovascular disease and peripheral vascular disease and reduction of TC and LDL-C below 442.86mg/dl and 116mg/dl, respectively, lowers the incidence of CHD. The lifetime risk of developing CHD after 40 years of age is 49% in men and 32% in women. Even at 70 years of age, the risk is 35% for men and 24% for women. 3 The lifetime risk of developing CVD at 50 years of age is estimated to be 1 in 2 for men and 2 in 5 for women in USA only. 4 Numerous epidemiologic investigations have suggested that age, sex, elevated LDL-ABSTRACT Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslipidemia.Methods: This open-label, randomized, parallel group, comparative, prospective study of six months duration included 100 patients. The age group of patients varied from 30 to 69 years with dyslipidemia. Patients were divided in to 2 groups. 50 patients in group-1 received Atorvastatin 10mg once daily and 50 patients in group-2 received Rosuvastatin 5 mg once daily. The level of TC, TG, LDL, VLDL and HDL were assessed at baseline and at the end of 3 months and 6 months. Results: At 3 months, LDL was reduced significantly more with 5mg Rosuvastatin than with Atorvastatin 10 mg [43.68% vs. 40.74% (P 0.0049)]. At 6 months, Rosuvastatin 5mg reduced LDL significantly more than Atorvastatin 10 mg [48.69% vs. 43.85% (P 0.00)]. TC, HDL, TG and VLDL were more favourably modified by Rosuvastatin at 6 months (P <0.005). Reduction of total cholesterol levels in Rosuvastatin group was not statistically significant when compared with Atorvastatin group (P 0.103). Conclusions: Rosuvastatin 5mg was more efficacious than Atorvastatin 10mg for the improvement of lipid profile during the period of 6 months follow-up drug therapy in patients with dyslipidemia.

show abstract

Section: Discussionsupporting

confidence: 76%

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Thapa¹,

Rai²,

Mahara³

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Similar findings were shown for pravastatin, which is nonlipophilic 22,23. Another study compared the effects of atorvastatin (10 mg) and rosuvastatin (10 mg) on changes in glucose and insulin levels, and the HOMA of the insulin resistance index, which were not significantly different between the two groups 24. Also, the result of a meta-analysis of randomized controlled trials may suggest that potential differences exist between statins 25.…”

Section: Discussionsupporting

confidence: 54%

Rosuvastatin Does Not Affect Fasting Glucose, Insulin Resistance, or Adiponectin in Patients with Mild to Moderate Hypertension

et al. 2013

View full text Add to dashboard Cite

The effects of statins on insulin resistance and new-onset diabetes are unclear. The purpose of this study was to evaluate the effects of rosuvastatin on insulin resistance and adiponectin in patients with mild to moderate hypertension. In a randomized, prospective, single-blind study, 53 hypertensive patients were randomly assigned to the control group (n=26) or the rosuvastatin (20 mg once daily) group (n=27) during an 8-week treatment period. Both groups showed significant improvements in systolic blood pressure and flow-mediated dilation (FMD) after 8 weeks of treatment. Rosuvastatin treatment improved total cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglyceride levels. The control and rosuvastatin treatment groups did not differ significantly in the change in HbA1c (3.0±10.1% vs. -1.3±12.7%; p=0.33), fasting glucose (-1.3±18.0% vs. 2.5±24.1%; p=0.69), or fasting insulin levels (5.2±70.5% vs. 22.6±133.2%; p=0.27) from baseline. Furthermore, the control and rosuvastatin treatment groups did not differ significantly in the change in the QUICKI insulin sensitivity index (mean change, 2.2±11.6% vs. 3.6±11.9%; p=0.64) or the HOMA index (11.6±94.9% vs. 32.4±176.7%; p=0.44). The plasma adiponectin level increased significantly in the rosuvastatin treatment group (p=0.046), but did not differ significantly from that in the control group (mean change, 23.2±28.4% vs. 23.1±27.6%; p=0.36). Eight weeks of rosuvastatin (20 mg) therapy resulted in no significant improvement or deterioration in fasting glucose levels, insulin resistance, or adiponectin levels in patients with mild to moderate hypertension.

show abstract

“…Our study demonstrates for the first time that rosuvastatin may improve IS in non‐diabetic patients compared with atorvastatin. Other comparative studies did not show changes in IR (5,6). The two statins had neutral impact on HbA 1c in our study with a trend towards reducing fasting plasma glucose levels (mainly with rosuvastatin).…”

Section: Discussionmentioning

confidence: 78%